GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis
Journal of the Endocrine Society · 04.11.2025 · 9 (12)
DOI: 10.1210/jendso/bvaf150 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the Endocrine Society, online erschienen am 11.11.2025. Verfasst von Klara Müller Alves und 3 weiteren Autor:innen. Beteiligte Einrichtung: Post-Graduate Program in Medical Sciences, Endocrinology, Federal University of Rio Grande do Sul, Porto Alegre 90035-903, Brazil. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Context
Individuals with psychiatric disorders have a higher prevalence of obesity, partly because of the use of psychotropic medications. Safe and effective pharmacological interventions for weight management in this population are needed.
Objective
To assess the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1Ras) in individuals with psychiatric disorders and obesity/overweight through a systematic review and meta-analysis, focusing on weight and metabolic outcomes. Data Sources We searched PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov until May 2025 for observational studies that evaluated GLP-1RAs in this population. Study Selection Studies including adults with psychiatric disorders and obesity treated with GLP-1RAs were eligible; 10 randomized controlled trials met the inclusion criteria. Data Extraction Two reviewers independently extracted the data and assessed the risk of bias using the Cochrane RoB 2 tool. Outcomes included weight, body mass index (BMI), waist circumference, glucose level, systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, triglycerides, and adverse events. Data Synthesis GLP-1RAs significantly reduced body weight [mean difference (MD) −5.03 kg; 95% confidence interval (CI): −6.04 to −4.01)], BMI (MD −1.59 kg/m²; 95% CI: −2 to −1.18), waist circumference (MD −3.4 cm 95% CI: −4.83 to−1.97), and fasting glucose (MD −0.29 mmol/L; 95% CI: −0.53 to −0.05) compared to controls. Gastrointestinal side effects were more frequent but generally mild and did not increase discontinuation rates.
Conclusion
GLP-1RAs are effective and well-tolerated for managing obesity in psychiatric populations, offering significant weight and metabolic benefits. Further studies are needed to evaluate newer agents, such as semaglutide and tirzepatide, particularly in longer trials with standardized protocols.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Post-Graduate Program in Medical Sciences, Endocrinology, Federal University of Rio Grande do Sul, Porto Alegre 90035-903, Brazil.
- Division of Endocrinology, University of Toronto, Toronto, ON M5T 3L9, Canada.
- Division of Endocrinology, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, Brazil.
ORCID-Profile: Klara Müller Alves, Manoela Teixeira da Silva, Caroline Kaercher Kramer, Luciana Verçoza Viana
Zitieren
APA
Müller Alves, K., Teixeira da Silva, M., Kramer, C. K., & Viana, L. V. (2025). GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis. Journal of the Endocrine Society, 9(12). https://doi.org/10.1210/jendso/bvaf150
Vancouver
Müller Alves K, Teixeira da Silva M, Kramer CK, Viana LV. GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis. Journal of the Endocrine Society. 2025;9(12). doi:10.1210/jendso/bvaf150
BibTeX
@article{MllerAlves2025,
author = {Müller Alves, Klara and Teixeira da Silva, Manoela and Kramer, Caroline Kaercher and Viana, Luciana Verçoza},
title = {GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis},
journal = {Journal of the Endocrine Society},
year = {2025},
volume = {9},
number = {12},
doi = {10.1210/jendso/bvaf150}
}
EUVIMED